Over the past several years, the clinical trial services market has experienced one of the most pronounced demand cycles in its history. What felt like structural acceleration at the time, particularly in the windfall of 2021, now appears to be far more nuanced: a funding-driven, lagged demand cycle, with meaningful implications for how investors are approaching the sector now and in the future. This clear distinction should matter to potential investors, as structural growth narratives potentially justify sustained, elevated multiples for assets within the sector. Cyclical dynamics, however, particularly those tied to external funding conditions, demand a more disciplined, timing-sensitive investment thesis.
Read the full article: Pharma Services Deep Dive: From Post-Pandemic Reset to the Next Cycle //
Source: https://www.lincolninternational.com/perspectives/articles/pharma-services-deep-dive-a-perspective-on-the-clinical-trial-services-market/